Rigel Pharmaceuticals has announced the enrolment of the first subject in a Phase Ib/II clinical trial of REZLIDHIA (olutasidenib) in combination with decitabine and venetoclax for patients with ...

The company is also making good progress with its second FDA-approved product, Rezlidhia (olutasidenib). The drug is indicated for the treatment of adult patients with relapsed or refractory (R/R ...

Fourth quarter 2024 total revenue of approximately $57.6 million, which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 ...

Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. Irrespective of how the ...

TAVALISSE Net Product Sales for Q4 2024: $31 million, a 21% increase year over year. REZLIDHIA Net Product Sales for Q4 2024: $7.4 million, a 92% increase year over year. GAVRETO Net Product Sales ...